| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.22 | 3e-05 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.21 | 0.2 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.17 | 0.002 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.17 | 2e-07 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.16 | 0.03 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.15 | 8e-06 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.14 | 0.7 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.07 |